search
Back to results

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Primary Purpose

Diabetes Mellitus Type 2

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Placebo
RG1511
Sponsored by
Hoffmann-La Roche
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus Type 2

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adult patients, 18-65 years of age;
  • type 2 diabetic patients;
  • naive to anti-diabetic therapy, or taken off current anti-diabetic therapy for >=2 weeks before first treatment.

Exclusion Criteria:

  • type 1 diabetes mellitus;
  • clinically significant cardiovascular disease.

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

4

Arm Description

Outcomes

Primary Outcome Measures

AEs, laboratory parameters, vital signs.
Glucose AUC

Secondary Outcome Measures

Insulin, C-peptide, glucagon and GLP-1 AUC
24h glucose
Lipid profiles
Pharmacokinetic parameters

Full Information

First Posted
August 16, 2007
Last Updated
November 1, 2016
Sponsor
Hoffmann-La Roche
search

1. Study Identification

Unique Protocol Identification Number
NCT00517465
Brief Title
A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.
Official Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multiple-ascending-dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of R1511 in Type 2 Diabetic (T2D) Patients
Study Type
Interventional

2. Study Status

Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
September 2007 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hoffmann-La Roche

4. Oversight

5. Study Description

Brief Summary
This 4 arm study will evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of R1511 compared to placebo in patients with type 2 diabetes mellitus. The starting dose of R1511 will be 100mg po bid for 5 1/2 days; this dose will be escalated in subsequent groups of patients to a potential maximum of 1200mg po bid for 5 1/2 days after a satisfactory assessment of blinded safety, tolerability, pharmacokinetic and pharmacodynamic data of the previous dose. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
41 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Title
2
Arm Type
Experimental
Arm Title
3
Arm Type
Experimental
Arm Title
4
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
po bid
Intervention Type
Drug
Intervention Name(s)
RG1511
Intervention Description
Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
Primary Outcome Measure Information:
Title
AEs, laboratory parameters, vital signs.
Time Frame
Throughout study
Title
Glucose AUC
Time Frame
Days -1, 1 and 8.
Secondary Outcome Measure Information:
Title
Insulin, C-peptide, glucagon and GLP-1 AUC
Time Frame
Days -1, 1 and 8
Title
24h glucose
Time Frame
Days -1, 1 and 8
Title
Lipid profiles
Time Frame
Days -1 and 8
Title
Pharmacokinetic parameters
Time Frame
Days 1 and 8

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adult patients, 18-65 years of age; type 2 diabetic patients; naive to anti-diabetic therapy, or taken off current anti-diabetic therapy for >=2 weeks before first treatment. Exclusion Criteria: type 1 diabetes mellitus; clinically significant cardiovascular disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Trials
Organizational Affiliation
Hoffmann-La Roche
Official's Role
Study Director
Facility Information:
City
Berlin
ZIP/Postal Code
14050
Country
Germany
City
Neuss
ZIP/Postal Code
41460
Country
Germany
City
Balatonfuered
ZIP/Postal Code
8230
Country
Hungary
City
Budapest
ZIP/Postal Code
1027
Country
Hungary
City
Bratislava
ZIP/Postal Code
82108
Country
Slovakia
City
Bratislava
ZIP/Postal Code
833 05
Country
Slovakia
City
Slough
ZIP/Postal Code
SL1 4AA
Country
United Kingdom
City
Welwyn Garden City
ZIP/Postal Code
AL7 1TW
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

We'll reach out to this number within 24 hrs